Market news

An affected mother says she cannot think of a worse diagnosis for a child than childhood dementia.

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Ultragenyx ​on Thursday set a U.S. list price of $3.95 million for its newly approved gene therapy Fayuvi, launching one of the world's most expensive drugs.

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx The Company received a Priority R

RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.

Rocket Companies (NYSE: RKT) today announced that Alessio Sanfilippo has been named Chief Executive Officer of Redfin, effective immediately. Sanfilippo joins Redfin from Meta, where he served as Vice President of Insights for Reality Labs.

Rocket (RKT) has named Alessio Sanfilippo as chief executive officer of its Redfin unit, effective i

John B. Sanfilippo & Son (NASDAQ:JBSS) outlined plans to expand its snack bar manufacturing business while continuing to build on its private-label nut and trail mix operations, during a presentation at the IDEAS Conference. The company, a fourth-generation family-managed processor, marketer and di

On August 20, John B. Sanfilippo & Sons (NASDAQ:JBSS) reported a fiscal year that looked strong on paper and a fourth quarter that told a messier story. Full-year net sales hit $1.18 billion, a record, while fourth-quarter diluted earnings per share fell 38.3% to $0.71. Volume returned to growth for the first time in five […]

Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.

The latest analyst update on John B. Sanfilippo & Son cuts fair value from US$109.00 to US$100.00, which is about an 8% reduction in the price target. Analysts link this shift to how they balance stronger revenue assumptions with more cautious views on margins and risk, and to where they see the stock on the current risk and reward spectrum. As you read on, you will see how these moving parts shape the evolving narrative around John B. Sanfilippo & Son and what to watch next. Stay updated as...

John B. Sanfilippo & Son (NASDAQ:JBSS) reported record fiscal 2026 net sales of $1.2 billion and a 4.6% increase in diluted earnings per share, although fourth-quarter profitability declined as higher costs, recall-related expenses and customer charges pressured margins. For the fiscal fourth q

Moby summary of John B. Sanfilippo & Son, Inc.'s Q4 2026 earnings call

John B. Sanfilippo (JBSS) delivered earnings and revenue surprises of -45.39% and +3.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

John B. Sanfilippo: Fiscal Q4 Earnings Snapshot

ELGIN, Ill., August 19, 2026--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the "Company") today announced financial results for its fiscal 2026 fourth quarter and full year ended June 25, 2026.

Elgin, IL, Aug. 12, 2026 (GLOBE NEWSWIRE) -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its fourth quarter Fiscal 2026 operating results on Thursday, August 20, 2026 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Fourth Quarter Results are expected to be released after the market closes on Wednesday August 19, 2026. To register for the call,

SOUTH SAN FRANCISCO, Calif., August 12, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce. The proceeds will be used to partially fund TA-ERT EAP, helping to broaden patient access to investi

Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.

Jasper Sanfilippo Jr. has worked at the company since 1991 and has been promoted from president and COO.

ELGIN, Ill., July 16, 2026--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) today announced a CEO and leadership succession plan designed to ensure a seamless leadership transition and the continued execution of its strategic plan. Jeffrey T. Sanfilippo, Chairman of the Board of Directors and Chief Executive Officer, will transition to the role of Executive Chairman, effective October 1, 2026. In this capacity, Mr. Sanfilippo will continue to lead the Board of Directors and work closely with the e

ELGIN, Ill., July 15, 2026--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the "Company") today announced that its Board of Directors (the "Board") declared a special cash dividend (the "Special Dividend") of $1.05 per share on all issued and outstanding shares of Common Stock of the Company and $1.05 per share on all issued and outstanding shares of Class A Common Stock of the Company. In addition to the Special Dividend, the Board declared a regular annual cash dividend (the "Annual Dividend")